HOME > Exhibitor News > Exhibitor News

Exhibitor News

PaxGenBio Co., Ltd. to exhibit ‘MPCR-ULFA platform technology', a Multiple Rapid Molecular Diagnosis System
2021-01-26 view : 520

PaxGenBio Co., Ltd. (CEO Park Young-seok, www.paxgenbio.com) will participate in the 36th Korea International Medical Device & Hospital Equipment Show (KIMES 2021) held at COEX in Seoul for four days from March 18 (Thu) to 21 (Sun).

 

MPCR-ULFA Technology diagram

 

Multiple rapid molecular diagnosis system' 'MPCR-ULFA (Multiplex PCR-Universal Lateral Flow Assay) platform technology' consists of multi-molecular diagnostic techniques that simultaneously amplify multiple genes and molecular rapid and accurate analysis of the results of multiple amplified genes. Multiple rapid molecular diagnosis technology is a gene-typing source technology with four patents registered, including U.S. patents, and is a quick and convenient molecular diagnosis kit that allows visual infection and genotype analysis.

 

PaxView® HPV 20 Genotyping MPCR-ULFA Kit

 

Based on the MPCR-ULFA platform technology, PaxgenBio is infected with human papilloma virus (HPV), a microorganism that causes cervical cancer, in particular, whether it is infected by types 16 and 18, which are the typical causes of cancer. PaxView® HPV 16/18/Others MPCR-ULFA Kit, which allows you to visually check the analysis results, and PaxView® HPV 20 Genotyping MPCR-ULFA Kit, which can analyze the genotype of 20 types of HPV, and can diagnose tuberculosis. PaxView® TB/NTM MPCR-ULFA Kit, PaxView® CT/NG/TP MPCR-ULFA Kit for simultaneously diagnosing chlamydia, gonorrhea, syphilis, and other sexually transmitted diseases, PaxView® SARS-CoV-2 MPCR-ULFA Kit was developed to diagnose Covid-19 infections.

 

PaxView® SARS-CoV-2 MPCR-ULFA Kit

 

Through the Korea International Cooperation Agency (KOICA) CTS project, Paxgenbio participated in the project to combat tuberculosis in Indonesia, the world's second highest prevalence rate of tuberculosis, and promoted overseas procurement markets such as the WHO, starting with the tuberculosis diagnosis kit and HPV diagnosis kit for high-risk groups in Asia. Through the discovery of major national agencies, entry into the South American market, and business development with global partners, we are promoting sales expansion to European and Chinese diagnostic testing centers for 20 HPV genotyping kits and major sexually transmitted diseases kits. the Corona 19 diagnostic kit is currently in discussions with the Philippine government for export.

 

PaxView®TB/NTM MPCR-ULFA Kit